Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 13.6a

Immunosuppression Use for Induction, 1999 to 2008

Recipients with Heart-Lung Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 51 48 27 33 29 40 35 31 31 27
With Immunosuppression Info 50 48 26 33 28 38 33 30 29 22
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 16.0% 29.2% 26.9% 15.2% 3.6% 13.2% 12.1% 3.3% 31.0% 13.6%
OKT3 10.0% 6.3% 0.0% 6.1% 3.6% 2.6% 3.0% 0.0% 6.9% 0.0%
Thymoglobulin 4.0% 4.2% 11.5% 3.0% 10.7% 13.2% 3.0% 6.7% 3.4% 0.0%
Zenapax 4.0% 12.5% 7.7% 15.2% 7.1% 18.4% 12.1% 16.7% 10.3% 40.9%
Simulect 0.0% 4.2% 30.8% 18.2% 17.9% 10.5% 24.2% 10.0% 24.1% 4.5%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 5.3% 9.1% 23.3% 17.2% 13.6%
No Induction Drugs Recorded 66.0% 47.9% 26.9% 42.4% 57.1% 42.1% 39.4% 40.0% 20.7% 27.3%


Source: OPTN/SRTR Data as of May 4, 2009.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.



PDF FormatRequires Adobe Acrobat Reader